Lifeboat Foundation

Multisystem inflammatory syndrome in children (MIS-C) onsets in COVID-19 patients with manifestations similar to Kawasaki disease (KD). Here the author probe the peripheral blood transcriptome of MIS-C patients to find signatures related to natural killer (NK) cell activation and CD8+ T cell exhaustion that are shared with KD patients.

A new kind of neural interface system that coordinates the activity of hundreds of tiny brain sensors could one day deepen understanding of the brain and lead to new medical therapies.

Materials that change their properties in response to certain stimuli could come to occupy a valuable space in many fields, ranging from robotics, to medical care, to advanced aircraft. A new example of this type of shape-shifting technology is modeled on ancient chain mail armor, enabling it to swiftly switch from flexible to stiff thanks to carefully arranged interlocking particles.

Contact Seller

Continue reading “Bulletproof chainmail? Next-gen fabric stiffens on demand” »

Yes this says a 3 year epigenetic clock reversal in just 8 weeks thanks to diet and lifestyle changes. There is a list of supplements too:

Alpha ketoglutarate, vitamin C and vitamin A curcumin, epigallocatechin gallate (EGCG), rosmarinic acid, quercetin, luteolin.

Manipulations to slow biological aging and extend healthspan are of interest given the societal and healthcare costs of our aging population. Herein we report on a randomized controlled clinical trial conducted among 43 healthy adult males between the ages of 50–72. The 8-week treatment program included diet, sleep, exercise and relaxation guidance, and supplemental probiotics and phytonutrients. The control group received no intervention. Genome-wide DNA methylation analysis was conducted on saliva samples using the Illumina Methylation Epic Array and DNAmAge was calculated using the online Horvath DNAmAge clock (2013). The diet and lifestyle treatment was associated with a 3.23 years decrease in DNAmAge compared with controls (p=0.018). DNAmAge of those in the treatment group decreased by an average 1.96 years by the end of the program compared to the same individuals at the beginning with a strong trend towards significance (p=0.066). Changes in blood biomarkers were significant for mean serum 5-methyltetrahydrofolate (+15%, p=0.004) and mean triglycerides (−25%, p=0.009). To our knowledge, this is the first randomized controlled study to suggest that specific diet and lifestyle interventions may reverse Horvath DNAmAge (2013) epigenetic aging in healthy adult males. Larger-scale and longer duration clinical trials are needed to confirm these findings, as well as investigation in other human populations.

Continue reading “Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial” »

🐶 Lifelike & Realistic Pets on Amazon: https://amzn.to/3uegCXk 🐱
🔥 Robot Dog Kit on Amazon: https://amzn.to/3jirOw9
🤖 Robot Dogs that are just like Real Dogs: https://youtu.be/pifs1DE-Ys4

▶ Subscribe: https://bit.ly/3eLtWLS

Continue reading “Shockingly Realistic AI Robot Dog ‘Jennie’” »

https://www.youtube.com/watch?v=PMQ-ViucOig

I think SENS did this last year but now AlphaFold2 will make it easier and faster.

Hey it’s Han from WrySci HX discussing how breakthroughs in the protein folding problem by AlphaFold 2 from DeepMind could combine with the SENS research foundation’s approach of allotopic mitochondrial gene expression to fight aging damage. More below ↓↓↓

Continue reading “A Specific Example of How AlphaFold 2 From DeepMind Could Help Us Achieve Immortality” »

It’s no secret that AI is everywhere, yet it’s not always clear when we’re interacting with it, let alone which specific techniques are at play. But one subset is easy to recognize: If the experience is intelligent and involves photos or videos, or is visual in any way, computer vision is likely working behind the scenes.

Computer vision is a subfield of AI, specifically of machine learning. If AI allows machines to “think,” then computer vision is what allows them to “see.” More technically, it enables machines to recognize, make sense of, and respond to visual information like photos, videos, and other visual inputs.

Over the last few years, computer vision has become a major driver of AI. The technique is used widely in industries like manufacturing, ecommerce, agriculture, automotive, and medicine, to name a few. It powers everything from interactive Snapchat lenses to sports broadcasts, AR-powered shopping, medical analysis, and autonomous driving capabilities. And by 2,022 the global market for the subfield is projected to reach $48.6 billion annually, up from just $6.6 billion in 2015.

For many years now, China has been the world’s factory. Even in 2,020 as other economies struggled with the effects of the pandemic, China’s manufacturing output was $3.854 trillion, up from the previous year, accounting for nearly a third of the global market.

But if you are still thinking of China’s factories as sweatshops, it’s probably time to change your perception. The Chinese economic recovery from its short-lived pandemic blip has been boosted by its world-beating adoption of artificial intelligence (AI). After overtaking the U.S. in 2,014 China now has a significant lead over the rest of the world in AI patent applications. In academia, China recently surpassed the U.S. in the number of both AI research publications and journal citations. Commercial applications are flourishing: a new wave of automation and AI infusion is crashing across a swath of sectors, combining software, hardware and robotics.

As a society, we have experienced three distinct industrial revolutions: steam power, electricity and information technology. I believe AI is the engine fueling the fourth industrial revolution globally, digitizing and automating everywhere. China is at the forefront in manifesting this unprecedented change.

U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration.

KENILWORTH, N.J. 0 June 17 2021 /PRNewswire/ — Merck (NYSE: MRK), known as MSD outside the United States and Canada 0 today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics.

“MSD is pleased to collaborate with the U.S. government on this new agreement that will provide Americans with COVID-19 access to molnupiravir – an investigational oral therapy being studied for outpatient use early in the course of disease – if it is authorized or approved,” said Rob Davis 0 president, MSD. “In addition to this agreement with the U.S. government, we are actively engaged in numerous efforts to make molnupiravir available globally to fulfill MSD’s commitment to widespread access.”